• iPS progeny production and the regulatory environment for cell therapies

• Sharing companies‘ perspectives and experience

• Safety risks and ethics in cell therapies

• Current State of the Art of iPS based heart repair: Large animal models and clinical translation

• Current State of the Art of heart support and beyond: Technical devices and human organ transplants